// App-Quantinova.ai

328 : Antitumor activity of the oncolytic peptide LTX-315 in syngeneic tumor models

Researchers

Presenter

  • Ketil Andre Camilio

Principal Investigators

  • Baldur Sveinbjrnsson

  • Sylvie Maubant

  • Guillaume Serin

  • Jean-Francois Mirjolet

  • Francis Bichat

  • ystein Rekdal

Medical Centers

  • Institute of Medical Biology, Tromso, Norway

  • Lytix Biopharma AS, Oslo, Norway

  • Oncodesign S.A., Dijon Cedex, France

Locations

  • France

  • Norway

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • LTX 315

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved